This suggests that a new generation of adenosine A2a receptor antagonists should be used at an earlier point in the progression of PD and in a manner where they are employed to be ‘levodopa sparing’ by avoiding further increases in levodopa dosage when the drug starts to exhibit a loss of efficacy. The gene discussed is ADORA2A; the disease is Parkinson disease.